John W. Hinds

Therapeutically targeting tumor microenvironment–mediated drug resistance in estrogen receptor–positive breast cancer

Kevin Shee, Wei Yang, John W. Hinds et al. · The Journal of Experimental Medicine · 2018 · 75 citations · Full text

Functional Heterogeneity of Breast Fibroblasts Is Defined by a Prostaglandin Secretory Phenotype that Promotes Expansion of Cancer-Stem Like Cells

Jenny A. Rudnick, Lisa M. Arendt, Ina Klebba et al. · PLoS ONE · 2011 · 55 citations · Full text

Breast Oncology, Prostaglandin Secretory Phenotype, Cell Proliferation +20

C3′/C4′‐Stereochemical Effects of Digitoxigenin α‐<scp>L</scp>‐/α‐<scp>D</scp>‐Glycoside in Cancer Cytotoxicity

John W. Hinds, Sean B. McKenna, Ehesan U. Sharif et al. · ChemMedChem · 2012 · 33 citations

Formation of a structurally-stable conformation by the intrinsically disordered MYC:TRRAP complex

Edmond J. Feris, John W. Hinds, Michael D. Cole · PLoS ONE · 2019 · 30 citations · Full text

Crystal Structure, Protein Assembly, Myc Protein +22

Selective Induction of Cellular Toxicity and Anti-tumor Efficacy by N-Methylpiperazinyl Diarylidenylpiperidone and its Pro-nitroxide Conjugate through ROS-mediated Mitochondrial Dysfunction and G2/M Cell-cycle Arrest in Human Pancreatic Cancer

Jesse M. Mast, John W. Hinds, Dan Tse et al. · Cell Biochemistry and Biophysics · 2020 · 23 citations

Tumor Biology, Pancreatic Cancer, Biochemistry +10